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Abstract 
Objective 
Evaluation of the respective contributions of short-term glycemic variability and mean daily 
glucose concentration to the risk of hypoglycemia in type 1 diabetes. 
Research design and methods 
One hundred persons with type 1 diabetes investigated at the University Hospital of 
Montpellier  (France) underwent continuous glucose monitoring (CGM) on two consecutive 
days (total of 200 24-h glycemic profiles). The following parameters were computed: the 
mean daily glucose exposure, (MDG), within-day glycemic variability (coefficient of variation 
for glucose, %CV), and the risk for hypoglycemia represented as percentage of time spent 
below three glycemic thresholds of 3.9, 3.45 and 3.0 mmol/L. 
Results 
MDG and %CV were significantly (p < 0.001) higher or lower, respectively, when comparing 
the 24-h glycemic profiles according to whether no time or certain duration of time was spent 
below the thresholds. Univariate regression analyses showed that the MDG and %CV were 
the two explanatory variables that entered the model with the outcome variable (the time 
spent below the thresholds). The Classification And Regression Tree (CART) procedure 
indicated that the predominant predictor for hypoglycemia was %CV when the threshold was 
3.0 mmol/L. In people with a mean glucose value ≤ 7.8 mmol/L, the time spent below 3.0 
mmol/L was lowest (p < 0.001) when the %CV was below 34%. 
Conclusions 
In type 1 diabetes, short-term glycemic variability relative to the mean glucose, i.e. %CV, 
explains more hypoglycemia than mean glucose alone when glucose threshold is 3.0 
mmol/L. Minimizing the risk of hypoglycemia requires a %CV below 34%.  
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Introduction 
It is well known that the fear of hypoglycemia is a major barrier in the optimization of insulin 
therapy in persons with type 1 diabetes (T1DM) [1,2] who prefer less stringent glycemic 
targets rather than incurring severe hypoglycemic episodes known to be associated with 
acute and chronic cardiovascular complications [3-5]. The seminal Diabetes Control and 
Complications Trial (DCCT) clearly demonstrated that intensive treatment in persons with 
T1DM resulted in increased rates of severe hypoglycemia compared to those less well 
controlled when expressed in terms of glycated hemoglobin [6]. The hypothesis that 
abnormally high daily glucose fluctuation, between peaks and nadirs, is also associated with 
an increased frequency of hypoglycemic episodes [7,8] has been confirmed in both 
observational and interventional studies [9-14] and mathematically modelised by Rodbard 
[15]. Consequently, from a “glucocentric” viewpoint, the therapeutic targets in the 
management of persons with type 1 diabetes should include the ambient hyperglycemia, the 
time in range [16-20], short-term glycemic variability [21-23] and the threshold for 
hypoglycemia [24,25]. Although it is highly likely that the mean daily glucose concentrations 
and glycemic variability are the two main explanatory factors that contribute to an increased 
risk of hypoglycemia, their respective contribution remains to be adequately investigated. 
The present observational and retrospective study in a population of type 1 diabetes 
undergoing continuous glucose monitoring (CGM) aims to determine the relative priority of 
the mean daily glucose (MDG) concentration and glycemic variability (%CV) to the time 
spent below 3.9 and 3.0 mmol/L [17-20] representing hypoglycemia.  
Research design and methods 
 Study design and participants 
After an initial screening procedure among a population of 163 persons with T1 DM who 
underwent a 3- day blinded CGM, a total of 100 persons were entered into the study, of 
which 88 were on multiple daily insulin injections and only 12 on continuous subcutaneous 
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insulin infusion (CSII). The relative low percentage of subjects treated with CSII is simply due 
to the fact that the study was conducted between 2006 and 2012, when CSII were less used 
than today. In all patients treated with multiple insulin injections, the basal insulin was 
glargine U100 administered prior to the evening meal. Pregnant patients and those less than 
20 years of age or who had experienced a recent illness or had been treated with steroids 
during the 3-month period preceding the investigation were excluded. All participants (65 
men and 35 women) attended the outpatient clinic of the University Hospital of Montpellier 
(France) for greater than 3 years with a diabetes duration of 5 years or more (mean duration 
of diabetes = 28 years). In addition their respective insulin treatments were stable for a 
minimum of 3 months prior to the investigation.  Continuous glycemic monitoring (CGM 
technology) was conducted on an ambulatory basis over a period of 3 days. Patients were 
also excluded from the final analysis if unexpected disruption in the glucose monitoring 
occurred, insufficient number of capillary blood tests or inappropriate calibrations. As 
recommended by the manufacturer of the CGM (the second generation Minimed System, 
Medtronic, Northridge, CA) four times daily finger stick determinations were performed on 
capillary blood samples. An acceptable calibration was based on an accuracy criterion 
defined by a correlation coefficient > 0.79 between paired readings. As mentioned above, all 
glycemic profiles were monitored on an ambulatory basis and all sensor insertions of CGM 
systems were performed by trained healthcare professionals at the diabetes outpatient clinic. 
The study was conducted in accordance with the Declaration of Helsinki each participant 
giving oral consent in accordance with European directive [26] that requires no approval from 
an ethics committee because of the non-interventional design of the study. 
Clinical investigation and laboratory determinations 
The three consecutive days of CGM avoided the weekend with the CGM sensor inserted on 
day 0 (before 1200h) and removed on day 3 at the same time of day. Chronic hyperglycemia 
(HbA1c) was assessed at baseline (study day 0) using a high-performance liquid 
chromatography assay [27] (Menarini Diagnostics; Florence, Italy). 
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Analysis of the data from the CGM 
The data recorded on the same day as the glucose sensor for GGM was inserted were 
excluded from the analysis in order to avoid any bias due to insufficient glucose stabilization 
between the sensor and the interstitial fluid during the first 24 hours after insertion of the 
device. Based on two validated 24-h glycemic profiles (at 5-min time intervals) on study days 
1 and 2 the total mean daily glucose exposure (MDG), short-term glycemic variability (%CV) 
and the presence of hypoglycemia (both symptomatic and asymptomatic) were assessed 
plus the cumulative time spent below three glycemic thresholds: 3.0, 3.45 and 3.9 mmol/L. 
As 100 patients were included in the present study and as two 24-h glycemic profiles per 
patient were performed, 200 glycemic profiles were suitable for analysis. Coefficients of 
variation for glucose (%CV) expressed as percentages were derived from the following 
computation: ([SD around the 24–h mean glucose value]/[24-h mean glucose]) x 100. In 
accordance with our own findings [11] the International Consensus on the use of CGM has 
now adopted the %CV as a reference to separate stable from labile diabetes [17]. The %CV 
has the main advantage of being the simplest metrics for assessing the short-term within-day 
glucose variability and secondly needs not to be adjusted for the mean daily glucose value. 
Due to its characteristics [28], the LBGI was not used in the present study as this metrics is 
necessarily highly correlated with the percentage of hypoglycemia [29] and, therefore, is 
more a marker to evaluate the risk of hypoglycemia than a potential causative factor for 
explaining the occurrence of hypoglycemic episodes. According to the recommendations of 
the International Hypoglycaemia Study Group [24], we consider that glucose concentration 
levels < 3.0 mmol/L detected by the CGM unequivocally indicate the presence of a clinical 
hypoglycemia. However, a glucose value < 3.9 mmol/L serves as an alert threshold when 
determinations are made on plasma venous samples [25]. As there are many uncertainties 
concerning the agreement between plasma venous glucose values and those recorded by 
the CGM, we decided to determine the times spent below 3.0 and 3.9 mmol/L with an 
intermediate glucose threshold set at 3.45 mmol/L, to indicate the presence/absence of 
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hypoglycemia. The time spent below the selected glucose thresholds was only recorded 
when the duration exceeded 15 minutes, i.e. three consecutive measurements at a 5-min 
interval.  
Statistical analysis 
 For descriptive analysis, variables were expressed as mean ± SD or median (interquartile 
range, IQR) and comparisons between groups were made using either the Student’s t test or 
the rank test of Wilcoxon-Mann-Whitney according to whether the data were normally 
distributed or not. 
 The statistical analysis was further oriented toward the goodness of fit for identifying and 
investigating the contributions of the independent (explanatory or predictor) variables (Xis) 
that can explain or predict the time spent below the three different selected glucose 
thresholds (dependent or outcome variables) referenced to as Ys. As the time spent below 
the thresholds was computed over a 24-h time interval all parameters recorded throughout 
the same period (the 24-h mean glucose concentration, within-day glucose variability and the 
daily insulin doses injected) were selected as Xis. This preliminary list was completed by 2 
additional variables: the age and body mass index (BMI) because both can play a potential 
role.  
A univariate analysis was conducted by calculating the simple linear regression between the 
dependent variables (Ys) and each potential explanatory variable (Xi). This statistical 
procedure was used for removing the independent variables that did not enter the model. 
Statistical significances given as p values were calculated after the time spent below glucose 
thresholds (normally expressed as percentage from 0 to 100%) had been converted into 
arcsin(square root of Y) [30] .This transformation was applied to the Ys in order to obtain an 
underlying distribution in agreement with the model linearity assumption. In addition the 
calculations used linear mixed-effect models because 2 values of Ys were obtained in each 
patient on two consecutive days of glucose monitoring.  The relationship between the Ys and 
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Xis was expressed as a linear simple regression function Y = βi Xi + α, in which each partial 
regression coefficient (i was an estimate of the relationship between Y and one given Xi. 
To reflect the initial units (Y expressed as percentages) the i coefficients were transformed 
back to proportions and then expressed as unitless standardized coefficients that provide 
indications of relative importance of the explanatory variables (Xi) in determining the value of 
the dependent variable (Y). 
 In order to estimate the respective influence of each remaining Xi variable upon the 
dependent variable Y, a sensitivity analysis using an arborescent regression (Classification 
And Regression Tree, CART) [31] was performed. The methodology of this approach 
consisted to include all potential explanatory variables at the top of the regression tree and to 
sequentially select those with the best splitting for establishing a hierarchy permitting to 
predict their role as primary or secondary key players in the expression of the dependent 
variable Y. During the first step of this top-down approach the data of the independent 
variable that showed the best sensitivity were separated into 2 homogeneous subsamples 
with a cut-off  (a node) value that served via a pruning procedure to either reject or maintain 
the data exhibiting a poor or high predictive value, respectively. The latter subsample with 
the highest predictive value was further submitted to the same procedure of splitting into 2 
subsamples, which ended when the independent variable showed its lowest sensitivity.  
 To gain further insight into the best fit between Y and each Xi value entering the model the 
Ys were transformed into natural logarithms. The relationships (rearranged as increasing or 
decreasing simple exponential curves as appropriate after reverse transformation of the 
ordinate scale of natural logarithms) were statistically tested between dependent and 
independent variables by using the coefficients of correlations (r values). Comparisons 
between r values were made after conversion into their corresponding values of Fisher ‘s z.  
Finally in the subset of 24-h glycemic profiles exhibiting mean daily glucose concentrations 
≤7.8mmo/L that correspond to eHbA1c levels  <6.5% (48 mmol/mol) [32], i.e. to a near 
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normal glycemic control [33], the time spent below 3.0 mmol/L was divided into tertiles for 
further statistical comparisons between medians and IQR using the rank test of Wilcoxon-
Mann-Whitney for unpaired asymmetrically distributed data.  
Analyses were performed with the R package, version 3.5.0 (The Foundation for Statistical 
Computing [www.r-project.org]) 
Results 
Demographic, clinical and laboratory characteristics of the patients at the time of 
enrollment in the study 
In the population considered as a whole (100 patients, and 200 glycemic profiles) means of 
the main parameters (± SD and range) are described as follows: HbA1c  = 8.27% (67 
mmol/mol) ± 0.99% (10.9 mmol/mol), range: 5.3 to 10.9% (34.3 to 95.9 mmol/mol), n =100; 
averaged mean daily glucose concentrations = 9.0 ± 2.4 mmol/L, range: 4.4 to 17.8 mmol/L, 
n= 200; %CV = 37.9% ± 11.5%, range: 82.0 to 94.8%, n =200; daily insulin doses = 0.67 ± 
0.20 units/kg/day, range = 0.37 to 1.21 units/kg/day, n=100; age = 55.7 ± 13.1 years, range = 
20.0 to 83.0 years, n= 100; BMI : 24.8 ± 3.1 kg/m2, range = 19.1 to 34.9 kg/m2, n =100. 
Comparison of glycemic profiles and clinical characteristics according to whether 
amounts of time were spent or not below the glucose thresholds 
The two hundred 24-h glycemic profiles recorded in the 100 participants were divided into 2 
categories according to whether no time or a positive amount of time was spent below the 
selected glucose thresholds of 3.0, 3.45 and 3.9 mmol/L (table 1). As expected, the number 
of glycemic profiles without any time spent below the selected thresholds was smaller when 
the glucose threshold was set at 3.0 mmol/L rather than at 3.9 mmol/L. Mean daily glucose 
concentration and %CV were significantly lower and higher, respectively, when glycemic 
profiles with glucose values below the thresholds were compared with those with no time 
spent below each of the three glucose thresholds. Daily insulin doses, age and body mass 
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index (BMI) did not differ across the different groups irrespective of the presence/absence of 
time spent below the glucose thresholds. 
Relationships between the times spent below the different thresholds (Y) and the 
independent variables (Xi) 
When the time spent below the selected thresholds (Y) was expressed as its arcsine 
transformation, i.e. the arcsin √Y, the univariate mixed regression analysis showed strong 
positive and negative relationships (p< 0.001) with the %CV and the mean daily glucose 
concentration (MDG), respectively. The unitless standardized partial coefficients of 
regression (βi) for the thresholds of 3.9, 3.45 and 3.0 mmol/L were positive for the %CV (β1 = 
+ 1.31, + 1.08 and + 0.75, respectively) and negative for MDG (β2 =  - 1.07, - 0.58 and - 0.35, 
respectively) indicating that the time spent below the selected glucose threshold increased 
with increasing %CV and decreasing mean glucose concentrations, respectively. In contrast, 
the remaining independent variables, i.e. the daily insulin doses, age and BMI did not 
correlate with the time spent below the different glucose thresholds. When the thresholds 
were set at 3.9, 3.45 and 3.0 mmol/L the respective p values were of 0.92, 0.91 and 0.60 for 
daily insulin doses; of 0.25, 0.16 and 0.24 for age and finally of 0.17; 0.13 and 0.07 for BMI. 
As a consequence the latter 3 variables were no longer considered to be explanatory, and 
were thus removed from the model of statistical analysis.  
Classification and regression trees 
As the statistical significances of %CV and mean daily glucose are both highly significant 
(P<0.001) we used the CART method (Classification and Regression Tree) to decipher 
whether one of them is more significant than the other. Different results were obtained when 
the three selected thresholds were tested (figure 1). At 3.9 mmol/L, the MDG was the first 
explanatory variable but when the glucose thresholds were set at 3.0 and 3.45 mmol/L the % 
CV appeared as the primary factor associated with higher risk of hypoglycemia (figure 1). 
When the threshold was set at 3.0 mmol/L, the %CV was the first variable that entered the 
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top of the regression tree. The first node of %CV for partitioning the tree was found at 47.3%. 
The subsample with the %CV below 47.3% was subsequently pruned from the regression 
tree and in this subsample the mean terminal value of the time spent below 3.0 mmol/L was 
of 1.7%. The subsample with the %CV ≥ 47.3% was retained for a further splitting. As 
expected, the second explanatory variable entering the regression tree was the MDG with a 
splitting node at 6.8 mmol/L. The subsamples with a MDG ≥ or < 6.8 mmol/L ended with 
mean time durations spent below 3.0 mmol/L, which were computed at 6.8 and 26.0 %, 
respectively, as indicated at the bottom of the terminal branches. 
Exponential relationships between the time spent below 3.0 mmol/L and the mean 
daily glucose or the %CV. 
The results are illustrated in figures 2a,b. The relationship between the percentages of time 
spent below 54 mg/dL (3.0 mmol/L) (Y) and the MDG (X, mg/dL) was described by a simple 
decreasing exponential curve: Y = 23.66 e-0.009x; r = - 0.358, p < 0.001. When Y was plotted 
against the % CV (X) the relationship was represented by a simple increasing exponential 
curve: Y = 0.93 e0.043x, r = 0.509, p < 0.001. The comparison between the 2 coefficients of 
correlation did not show any significant difference by testing the corresponding z values after 
Fisher’s transformation = 1.87, p = 0.065, even though the r value for the %CV seemed to be 
slightly better than that for the MDG. 
Time spent below 3.0 mmol/L after dividing the %CV into tertiles in the subset selected 
by mean glucose values less than 7.8 mmol/L 
Among the 200 daily glycemic profiles, 65 exhibited mean glucose concentrations ≤ 7.8 
mmol/L. After dividing this subset by %CV the following tertiles were selected: 1 (%CV <34%, 
n = 21); 2 (%CV between 34 and 44.1%, n = 22); and 3 (%CV >44.1%, n = 22). As illustrated 
in figure 3 percentages of time spent below 3.0 mmol/L (medians [IQR]) were statistically 
greater in the upper tertile 3 (15.6% [IQR= 20.5%]) when compared with the two others: 
 12 
p<0.001 vs tertile 1 (0.0 % [IQR= 2.7%]) and p<0.01 vs tertile 2 (3.1% [IQR= 5.5%]). No 
difference was found between tertiles 1 and 2.  
Discussion 
Several key messages can be drawn from the present study. Firstly, the two main factors for 
predicting the risk of hypoglycemia in persons with type 1 diabetes are low or near normal 
daily glucose levels and abnormally high glucose fluctuations from peaks to nadirs. Secondly 
the role of these two factors was found to be approximately equivalent across the range of 
glucose thresholds from 3.9 to 3.0 mmol/L even though excessive within-day glucose 
fluctuations appeared to be increasingly involved in predicting the risk of hypoglycemic 
episodes and precipitating their onset with decreasing the glucose threshold used for 
defining hypoglycemia. In addition the coefficient of correlation of the exponential curve 
depicting the relationship between the time spent below 3.0 mmol/L and the %CV was found 
to be greater than that for the mean daily glucose value as explanatory variable even though 
the differences were not statistically significant. Similar findings derived from a less 
sophisticated mathematical analysis were observed for the %CV and were reported recently 
at the 2018 meeting of the American Diabetes Association [34]. Nevertheless, all these 
results reinforce the opinion that besides achieving near normal glycemia for preventing the 
development or progression of micro and macrovascular complications [6,35-38], it is crucial 
to try to reduce as much as possible the magnitude of glucose swings in order to limit the risk 
of hypoglycemia, a major challenge for improving the quality of life of persons with type 1 
diabetes [7-14]. This position is supported by two additional findings. Firstly in all groups the 
averaged %CV were below 36% (the limit that separates stable from labile diabetes [11,17]) 
when the patients did not spent any time below the selected thresholds, whatever the values 
chosen from 3.9 to 3.0 mmol/L. By contrast, the averaged %CV was always above 36% 
when the patients spent a positive amount of time above the aforementioned glucose 
thresholds. Secondly the computation by tertiles of %CV in the subset with near normal 
mean daily glucose values showed that the amount of time spent below 3.0 mmol/L was 
 13 
rarely positive when the %CV was less than 34%. Therefore, maintaining the %CV below this 
threshold should be a suitable recommendation for limiting the risk of hypoglycemia when the 
mean daily glucose concentration is stabilized and maintained below 7.8 mmol/L, i.e. a value 
that corresponds to a near normal glucose exposure [32,33]. Even though the two thresholds 
of 36 and 34% are very close their meaning is quite different. A %CV above 36% is 
synonymous of frequent hypoglycemic episodes (labile diabetes) regardless of mean daily 
glucose concentrations whereas achieving a %CV below 34% ensures a very low risk of 
hypoglycemia when a tight glycemic control is obtained in terms of overall glucose exposure. 
Until recently only a limited number of people with type 1 diabetes concomitantly attained 
such targets of low %CV and near normal mean daily glucose concentration with 
conventional insulin treatments consisting either of daily multi-injections or even continuous 
subcutaneous insulin infusion with pumps [39]. However, the expanded use of novel devices 
for continuous glucose monitoring [17,40,41] or the ceaseless progression towards the 
implementation of more and more sophisticated systems for closed-loop insulin delivery [42] 
raise both promising expectations for improving the glucose homeostasis in persons with 
type 1 diabetes. Even though it is highly likely that the reduction in short-term glycemic 
variability is one of the key player for the diminution in the incidence of hypoglycemia, the 
observation of a strong relationship between the %CV and the time spent below different 
glucose thresholds does not permit to distinguish whether glucose variability is the cause or 
the consequence with regard to the time spent below the recommended target glycemic 
range usually set between 3.9 and 10 mmol/L [17,18,20]. It should be noted that the present 
study was conducted in patients who were carefully instructed to ingest moderate amounts of 
refined carbohydrates in order to prevent excessive glycemic rebounds during post- 
hypoglycemic periods and thus to avoid any subsequent additional deterioration of glucose 
variability. Furthermore as the CGM data were masked to the patients throughout the entire 
monitoring period, all asymptomatic hypoglycemia were not subject to therapeutic 
interventional measures of correction in the absence of any warning signs. Consequently 
there are many reasons to consider that excessive glucose variability is more a causative 
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factor of hypoglycemia than its consequence. This study has some limitations due to its 
observational design, the short duration of the study period albeit all CGM were conducted 
on an ambulatory basis, and finally the potential inaccuracy of sensors when glucose values 
are within the lower range of the CGM.   
In conclusion and addressing the question raised in the title of this article it appears that the 
excess of short-term glycemic variability assessed from the within-day coefficient of variation 
for glucose is at least equivalent to and perhaps slightly more important than the mean daily 
glucose level to prevent the risk of hypoglycemia, especially when the threshold of 
hypoglycemia is set at its lower level of 3.0 mmol/L. In addition striving to achieve a %CV 
below 34% in patients who have already a satisfactory glycemic control in terms of chronic 
glucose exposure (mean daily glucose concentration ≤7.8 mmol/L) should be one of the main 
objectives in the management of type 1 diabetes.  
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*p < 0.001 
Table 1: Glycemic profiles were separated into 2 groups according to whether they exhibit 
(yes) or not (no) a significant duration of time (>15 min) spent below different thresholds i.e. 
3.0, 3.45 and 3.9 mmol/L. Statistical comparisons between glycemic profiles (referenced to 
as yes or no) were only indicated when p values < 0.001. 
 
Thresholds set at 3.0 mmol/L 3.45 mmol/L 3.9 mmol/L 
 No Yes No Yes No Yes 
N° of glycemic 
profiles 
120 80 100 100 71 129 
Age (years) 56±14 53±12 56±14 53±12 57±14 54±12 
BMI (kg/m2) 24.5±3.0 25.5±2.9 24.6±3.1 25.2±2.9 24.7±3.1 25.0±3.0 
MDG (mmol/L) 9.8±2.4* 7.9±2.0 10±2.4* 8.0±2.0 10.4±2.3* 8.2±2.2 
%CV for glucose 
(%) 
33±9* 44±11 32±9* 43±11 31±9* 42±11 
Insulin dose 
(units/kg/day) 
0.66±0.20 0.68±0.19 0.66±0.20 0.67±0.20 0.67±0.20 0.66±0.20 
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Legends of figures 
 
Figure 1: Classification and regression tree (CART) procedure. 
The respective influences of the potential explanatory variables (the mean daily glucose 
concentration and the %CV) upon the dependent variable (the time spent below the 
selected thresholds: 3.9, 3.45 and 3.0 mmol/L) are estimated using the CART. The 
subsamples splitted from the threshold values (nodes of the open circles) are considered 
to be the best true (right branch) or false predictors (left branch) for the risk of 
hypoglycemia assessed from the percentage of time spent below 3.9, 3.45 and 3.0 
mmol/L. For instance a Yend value of 26.0 at the end of the right branch of the regression 
tree (threshold <3.0 mmol/L) means that after a true stepwise splitting that selected the 
1st (%CV) and 2nd (MDG) line explanatory variables the averaged percentage of time 
spent below 3.0 mmol/L is of 26.0 %. When these explanatory variables are not truly 
selected the final percentage is only of 1.7 %. In summary, the right itinerary that has 
selected the %CV and the MDG as first and second explanatory variables, respectively, 
at thresholds of 47.3% for the %CV and 6.8 mmol/L for the MDG, corresponds to the best 
selection with the highest sensitivity (26%). 
Figure 2: Simple exponential relationships 
 The time spent below 3.0 mmol/L is plotted against the mean daily glucose 
concentration (figure 2a) or the coefficient of variation for glucose (figure 2b). 
Figure 3: Percentages of time spent below 3.0 mmol/L  
The data of %CV were divided into tertiles in the subset of 65 daily glycemic profiles 
exhibiting mean glucose concentrations ≤7.8 mmol/L. Data distributions around medians 
are expressed as interquartile ranges (IQR illustrated by boxes), 90th percentiles 
(illustrated by vertical lines and their upper and lower limits) and ranges from minimum to 
maximum. 
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